Recomendações
Entrada é o preço de fechamento do ativo na data de publicação. Atual é o último fechamento registrado.
-
Entrada $71,60 13 nov 2026Atual $54,04 20 nov 2026Resultado −$17,56vs. índice −16,0% SPY −8,6% no mesmo período
Citar esta recomendação Ver trecho original (1278s) *
Contexto da transcrição original
… it make a push for all-time highs. And that all-time high was uh October 2025 around 103. I think we get above that to 110. So, I think in the short term, we got pretty good upside here. And the long-term fundamentals also look great. So, Tempest stock has my stamp of approval in this current market. [snorts] That's awesome. Is there a conflict of interest between Tempest and ADPT like uh with its you know kind of data mode? Would it essentially eat ADPT's lunch in the the future if its models keep growing? >> Conflict of interest. I m…
Tempest stock has my stamp of approval in this current market.
Contexto extraído por IA So, I think in the short term, we got pretty good upside here. And the long-term fundamentals also look great. So, Tempest stock has my stamp of approval in this current market.
Transcrição Completa
The AI data center trade is transitioning, not ending. The transition is painful and it may not be over. Maybe more shoes to drop, if you will, more legs lower, if you will, but eventually we are going to bottom. And when we do bottom, I think it's going to be a massive rebound rally. On the other side, as the market adjusts to the new normal of stable, but still high capital spending plans from the hyperscalers. >> Hello and welcome to Being Exponential. Today, we're going to be covering our five stocks of the week. Uh so Luke, we've had a almost broad spectrum of stocks here this week. Um let's start off with Cloudflare NE. >> Yeah, Brooke. So I think that the the setup for the market is dramatically changed over the last week. Um the price action has been very violent and some major technical levels are are breaking and fundamental conditions have changed too. And so I think in response to that, you know, our thesis has been AI with AI, which has been expressed through being allin with the AI supply chain stocks, the uh Nebuses of the world, the Marvel's of the world, the Broadcoms of the world, the AMDs of the world, the Nvidas of the world, the recent networks of the world, etc., etc. that trade is under significant pressure. Has been under significant pressure and it looks like the pressure there could persist for a little while longer. I don't think the trade is dead by any means. We'll talk about that in our macro podcast, but I do think that that there is more pressure there uh in the short term and that things could get worse before they get better. So, this episode I want to focus on stocks that I think can weather that storm really well. There are parts of the market that despite the broader weakness and despite the specific weakness in the AI trade have done pretty well in the last month, in the last 3 months, in the last 6 months and these are the stocks that I think investors can find shelter in during this very turbulent period for the AI trade. And so one of them is Cloudflare. Now Cloudflare obviously that's the cyber security play. We've talked about cyber before when we had JR on the podcast. We didn't talk about Cloudflare specifically, but that's probably my favorite name in the entire cyber space because they're basically the the doorman for the internet. So that anytime there's traffic on the internet, the internet or somebody wants to go on a website, they're sort of the doorman allowing traffic into that website. That's really important in the era of aentic AI because internet traffic is one going to grow dramatically. We've already seen that because it's not users anymore. It's agents and every user can have 10 20 30 40 50 hundreds of agents that are constantly running throughout the internet. So internet traffic grows exponentially in the era of agentic AI. And two, these agents have different behaviors than humans and they have different intentions. And is it a rogue agent? Is it a planned agent? What what's the intention behind the action that it's doing? So the sort of behavioral analysis of the doorman also has to fundamentally change. And so I think those are two massive tailwinds for a company that protects websites, that protects the internet, if you will. And that's Cloudflare. Cloudflare is the king of this space. They are the big dog. They are a massive growth company. And I really like the setup here because they just reported earnings. Earnings were fantastic. This is a stock that you can see here in the chart. It pulled back pretty dramatically, right? This is a stock that topped out right around 350 uh in late September, early October, and then it crashed all the way to 250 right at the 200 day. And then look at this V-shaped recovery. Like that is exactly what you want to see. One of our favorite setups is long-term winner and a short-term pullback that is now U-turning. It's exactly what you have here. Long-term winner, short-term pullback now U-turning at the most important technical support level. And better yet, it's bouncing because of a strong fundamental catalyst with their recent earnings report last week. That was absolutely fantastic. The caveat here is you're paying a crap ton for the stock. 163 times forward earnings, 106 times forward EVATHAW. But as you can see on a 2-year basis, that's actually below average on the PE multiple, a little bit below average on the EVAT multiple. So, I really don't think this one is like the valuation should be that much of a headwind. I really like Cloudflare here. I like the cyerspace. We talked about that previously, but we missed my favorite stock and that's Cloudflare. I think the entry point here on a bounce off the 200 day is really attractive. >> Awesome. Yeah, I mean the the the valuations are almost the MMO for these cyber security stocks. So I have two kind of follow-ups here, Luke. Um, one is almost tangential. So you mentioned the AI agents thing. So notably, I think JB Diamond banned the use of AI agents in online baking. Do you think that would be more pervasive in, you know, the broader market where companies are disallowing the use of agents? >> No, I think the use of agents is going to it's going to be enormous. I I don't and these are like kind of one-off cases where it gets banned here, banned there, and where it gets banned, it's part of the temporary pause. It's more of like let's think about how we're going to use them and then let's use them responsibly. Kind of like what's going on with the data center uh trade, right? It's not an outright stalling in uh capital expenditures for building new data centers, but it's now like, okay, let's sit back and think about how we can do this more responsibly. Um that's sort of how I view the agent trade, too. So I don't think the agent the growth of agents is a trend that's going to stop anytime soon. Um I think there may be pauses here and there but the overall trend will be exponential growth in agentic traffic on the internet and that is a exponential tailwind for a stock like cloud player. Of course agreed and then second and this is kind of a broader question for all of these stocks. So to clarify this isn't a rotation out of our you know core AI trades. This is more of a broadening of our portfolio to kind of hedge it. Is that is that right? Yeah, [clears throat] I would I would say that yes and no. It we're in a very confusing period for the markets. We'll talk about it a lot more in the macro podcast coming up, but >> we're in a very confusing period where things could go either way. Um the the demand for AI is still amazing and sensational. And if that were the only thing that mattered, then the trade is very much alive and well. But it's not the only thing that matters that Washington has entered the conversation. Wall Street has entered the conversation. Supply chain shortages have entered the conversation. And so these three non-demand related factors can put significant downward pressure on the data center trade, the AI data center trade in the short term. I I don't think it says anything about the 12 to 24 to 36-month outlook on these stocks, but it does say a lot about the uncertainty over the next 3 to 6 months. And I think it's very likely that we do see capital expenditures from the hyperscalers come in lower than expected for 2027 and 2028, lower than planned. And so if that happens, remember our previous podcast was you got to fundamentally ask yourself the question, will the hypers scalers stop spending? Will they reduce their spending? If no, stay bullish. If yes, get cautious. In the last week, enough factors have changed for me. When I ask that question now, I have to say it won't slow, but it's probably not going to grow a whole bunch. And the problem with that is that the estimates price in hyperscaler capex growth into like 2030 and those estimates are probably wrong. We probably st we probably get a big jump in 27 that's smaller than expected and then 28 2930 are probably stable levels of spending which means those capex estimates have to come down and if the capex estimates come down that means the receiving end has to come down as well the EPS estimates for the entire AI supply chain. So, I think we're kind of due for downward revisions in a lot of those estimates and that can put pressure on the trade in the short term, but we're going to find a steady state on the other end of that transition where it's like, okay, these earnings are still big now. They're at a base. Now, they can grow sustainably and the trade rebounds like crazy. I think we're going to get one of the best buying opportunities uh in the last 25 years in tech stocks in the next 3 months, but I don't think it's right now. So that's why we're focusing on sort of okay the AI trade is you know put on hold put on pause it's in timeout it's in the corner that core data center trade these are stocks that you can play in the meantime in my opinion while that data center trade is kind of in in the timeout zone definitely and yeah of course we're going to dig into that more in the macro episode. Uh but next up let's uh talk about JROG. So they reported 31% revenue growth and their cloud revenue increased over 60%. Yeah, J J J J J J J J J J J J J J J J J J J J J J Frog's a stud. JROG is the exact type of stock you want to own in this environment because it's a type of stock that kind of like Cloudflare, but even more uh emphatically has a ton of exposure to growth in AI adoption, but not a ton of exposure to AI capex. So the data center buildout can slow or stall or whatever word you want to use and it won't impact JFrog because like I said that slowdown is not demand driven. It's Washington driven, Wall Street driven, supply chain driven. Demand is still there. So if you have a non-demand driven slowdown, yes, that's going to hurt the supply chain companies, but it's not going to hurt the application layer. And JROG is at that application layer really like every line the 400t bold thesis here is that every line of code that an AI writes becomes a software file that has to be stored and secured and tracked. And that is JROG's whole business. They kind of create that software if you will that stores, secures and tracks essentially every line of AI software code. So the idea is that more AI code, more demand for JROG, higher revenues, higher profits. And that's exactly what you saw in their in their earnings report. If we kind of pull up the numbers here, I mean, you kind of named a few, but yeah, I mean, revenues are up 31%, cloud revenue is 60% of sales. Contracted future revenue, their their RPO, remaining performance obligations up 60%. Uh, net retention of 124%, which is ridiculous. Gross retention of 97%. uh they grew their number of big ticket customers, $1 million plus customers uh by 60% in the quarter, 58%. Uh the guide was way above expectations on both revenue and EPS. I mean, it was just like it was a fantastic report and the stock obviously soared like crazy. And if you look at the chart, like I said, we want to look for stocks that have been working in the chaos. Frog is a stock that has been working in the chaos. Look at that. It just it's sprinting to new highs. It was the stock that had this consolidation for a bit, dropped to the 200 day moving average and is now blasting higher to new highs. That's that's fantastic to see. RSI is not overbought. It's right around just below 60. You got a bullish MACD crossover. You got great momentum. Uh the growth profile here is absolutely uh amazing when you look at uh the outyear estimates. And again, these estimates feel stable to me because it's tied to AI adoption, not AI capex. So you got basically compounded 20% revenue growth in the top line. It's an 80% plus gross margin business with stable EVA margins. You have 20% plus on the bottom line. And you're not paying all that much for it here. When you look at the valuation for that, you're only paying I mean 81 times sounds like a lot, but on eBay you're paying 68.5 times. You're on the upper end of the valuation range, but it's really not super expensive for a high margin, high cash flow, high growth company tied to the biggest tailwind in the economy right now. So JROG to me is the exact type of stock that you want to own at this moment. I really like this one. >> Excellent. Yeah, love that. All right, so next up, uh we're going into the biotech sector. Uh >> relatively seasonal sector. Uh first up is adaptive biotechnologies, ADPT. >> Right. Right. So the the big picture both these is so biotech's been having a moment. Biotech stocks have been doing really well. Healthcare stocks have been doing really well. Again the continuing this theme of looking for stocks that have done well in the chaos. Biotech and healthcare. Those are two sectors that have done really really well in the chaos. Now what adaptive does is they own the leading tests for spotting the last traces of blood cancer after treatment. uh medical guidelines are moving toward testing patients more often uh which should give the company years of steady profitable growth with no link again to this AI capex slowdown. So it's a company that has some AIdriven tailwinds. They're using AI with a lot of that testing. They have an AI subdivision. Um the growth is is strong and it's independent of the capital spending trends uh or capital spending plans of the hyperscalers. Um their their main product is this this clono secq they call it which is a blood or bone marrow test for cancers like multiple uh meal leukemia and lymphia. That test is growing very very very quickly. believe you kind of pull up the numbers on their recent results here. Um, yeah, I mean that though the the number of those clonq test was 39,587 which is up 60 or 46% uh year-over-year. Massive growth there. And if you look at the growth but it's supposed to persist. Look at the growth profile for ADPT going out to 2029. And let's pull up those estimates again. So big growth 22 24 16 18 call it compounded 20 gross margin 74 up to 77. The most attractive thing about this is we're going to finish the year at 3% EVA margins. When you have a 20% plus topline grower with 70% plus gross margins that is only at 3% EBA margins. That either means one the company is very poorly run or two there's a lot of room for operating leverage over the next several years. That's exactly what's expecting here. Ibida margins running from 3 million or 3% rather 9 million to 29% and $183 million. So this is one of the biggest Ebida growth profiles in the market right now. Very attractive. Now the valuation is a little steep but I don't think it's steep enough considering that growth profile 108.4 times Ebad. But if you look over here and you see I thought gets up to $200 million. Okay, $200 million a stock like this can trade it easily, you know, 40 50 times the earnings or even 200 on 50 is 10 billion. That's a double in like two or three years. So, this is a stock that I think the valuation has room to expand. I also think those outyear estimates, excuse [clears throat] me, move higher and then you look at the chart and the chart again is just really attractive. What has been working? Look at this chart. This has been working. Great uptrend on the stock. came [snorts] into its 100 day bounce back into its 100 day bounce about to make a new high actually is at a new high maximum draw down right now is 0% so it did make a new high today RSI is not overbought MACD looks good momentum looks good this is a winning stock it's got upside this is a a good play amidst the recent chaos >> yeah that's that's awesome a blood test that actually works um so with actually works there you go >> so with uh with their MN and uh their minimum residue residual disease testing. It's not currently routine. If it does become a routine part of cancer treatment, do we have an idea of what that TAM is, how much growth we can expect from that's why I think these estimates are low, right? I mean, I think you're right. The MRD business is working, but it's not I mean, it's the main engine of growth, but it could be a lot bigger than what it is today. And if that starts to really kick in, I don't think his estimates price that in. And so like I said, I use 200 million EBA as kind of like an exit goal for 2030. We could probably get to 300 or 400 million. We probably double that and then all of a sudden, you know, the valuation here can get really really big. So this is a stock that even on conservative estimates doesn't look overvalued right now. And if you get, you know, more aggressive estimates b uh baked in there, it's a stock that could really fly. So I I really like this one. It's been on an uptrend for a while, right? You look at the long-term chart. really kind of bottomed in late 24, early 24 at around, you know, two bucks and change and now it's 30. So 15 bagger if you want to look at it from that perspective. I just think this uptrend has a lot of runways and this is a good company and it's a good stock and so I think this is a good time to to play defense if you will with it. >> Awesome. Okay, so moving on to another company pretty similar or similar enough Tempest AI which is a true AI healthcare uh platform, >> right? Uh, yep. Yeah. I mean, so again, Biotech Healthcare, it's been working, so let's go with what's working. Tempest has been one of our favorite companies at the AI application layer for a very long time. It's been a very volatile stock, but it's starting to really have a moment in the market. Uh, what the company's done is they've essentially, they're pioneering personalized AI medicine. Uh, which is this whole idea that with AI, we can personalize healthcare treatments to you. And not just a general treatment, but a personalized treatment to you. And obviously the the fuel of that and what determines how the efficacy of a personalized AI healthcare treatment plan is going to be the underlying data. And Tempest has built one of the largest collections of patient data in the entire medical industry. and they are leveraging that data to create very robust AI algorithms and then partnering with very large health care firms to pioneer personalized AI health care treatments. And so this is a company that again I think is they're in the early innings of a massive massive growth burst. Uh they just reported earnings was like a week or two ago. Really good numbers. We can pull those up here. Revenue was up 23% year-over-year. Uh their cancer test volume was up 32%. Their data and AI revenue was up 33%. Adjusted EBA jumped from 1.5 million to 25.6 uh million really just absolutely crushing it. Uh bookings guidance was strong. Revenue guidance was strong. You look at the growth profile here 26% this year on the top line 2421 2017. No AI capex exposure here. those estimates can probably drift higher. Very similar situation as you have with ADB ADPT where you have a high gross margin business. This that one was 70% plus this one is 65% plus inching towards 70 trading at a low singledigit uh EBID margin marbot margin right now 4%. So that can you know through operating leverage get from 4 to 24 and EVO goes from 65 to 800 million and I think actually I think 2030 do could look more like a billion and again stock like this high growth high margin high cash flow biotech company or healthcare technology company whatever you want to call it uh can trade at you know 40x earnings or 40x pretty easily. So if this gets to a billy by 2030, you put 40 on it, that's 40 billion. And we're at 15 billion now. So that's a lot of upside in the next three years. And so I think this one has a lot of fundamental driven upside. And then when you look at the chart, it's really starting to flash some breakout signals to me. You know, Tempest AI, like I said, it's been a volatile stock. It's kind of gone, it's yo-yoed quite a bit, but right now it's yo-yoing up. And I think that yo-yo up has has runway. You can see again, I kind of want to just show the volatility in this name. Uh, it's been very volatile for a while. Had that big run in 25 and then gave it all back pretty much. And now we're having another big run. The fact that we're breaking above there's this big peak right here right around what is that 72. We crushed through that. Had this big peak around 77. Crushed through that. So, the fact that we're crushing these previous peaks tells me we're at least getting a 90. You know, this high from February and then some highs back here. in September. We're going to at least get the 90 on this one. And I think we're actually given the cycle turn. You know, the 50 above the 100, above the 200, 200 slope, now turning higher. This looks like a pretty big turn. And so, I think it make a push for all-time highs. And that all-time high was uh October 2025 around 103. I think we get above that to 110. So, I think in the short term, we got pretty good upside here. And the long-term fundamentals also look great. So, Tempest stock has my stamp of approval in this current market. [snorts] That's awesome. Is there a conflict of interest between Tempest and ADPT like uh with its you know kind of data mode? Would it essentially eat ADPT's lunch in the the future if its models keep growing? >> Conflict of interest. I mean I don't know if it's conflict of interest. They are they are competitive in a very growing market but it's kind of like AMD and Nvidia. Uh it's kind of like Arisa Networks and Lum. And it's kind of like there's just there's a lot of growth in this area uh of the biotech world, you know, using AI to improve clinical outcomes. And I do think our healthcare outcomes and patient outcomes. And I do think that Tempest and ADPT and there's some others out there can succeed side by side. They're not going to be rubbing elbows. There's a lot of green space in this pasture, a lot of open uh space in this pasture and so I don't think they're going to be rubbing elbows for a very, very long time. >> Roger that. Okay. Uh, last but certainly not least, the healthc care giant Eli Liy. Uh, LL Y. >> Yeah. I mean, Lily. So, the the growth engine of the market in the last three years has been two really. One AI and then number two by a wide margin, you know, big distance. But there was a number two and that was GLP's, right? That was the weight loss stuff. >> Uh, and these guys are just absolutely crushing it there. I mean, Monaro, Zetbound. These GLP-1 style drugs are all the rage. They're moving into pill form. Um the uh what do they call it? Foundo, right? Fondo is a daily weight loss pill they just launched. Uh and I think with that, the growth runway, everybody was doubting the growth runway for the GLP1s, right? Everyone's like, "Okay, everyone got the shot. Now what?" Well, the growth runway extends dramatically with the pill. There are so many people out there that just will not take a shot. But you make a weight loss an effective weight loss pill and all of a sudden you increase the market by a dramatic amount. And so I think there's just really big growth here yet to come that is not priced into the stock because of the runway extension of the pill. Um Eli Liy look at the growth profile. See here's here's the thing I like about the stock. You have this dramatic slowdown priced in revenues up 40% this year and then 16 12 97 that's a massive deceleration when this was a 45 46 40% growth company now you're going to get into mid- teens all the way down to single digits I don't think so I think the pill keeps us above 15 if not above 20 for the next two to three years so these estimates got to move higher they will move higher which means the margin estimates are going to move higher because look Look at this. You're at 46% even without the day going up to 57. Maybe you're 46 to 67. So all of a sudden you get a, you know, a 20% uplift on 2030 revenues and you add 10 points of margin expansion, you get a 30 40% uplift on IBIT estimates. And so I think there's a huge uplift to come on those IBIT estimates. And when you look at the valuation, it's just again it's not priced for accelerating growth. Not accelerating growth, but for stable and high growth. You look at that. I mean 29 time forward earnings is essentially a five-year low. 24 time forward Ebot is essentially a five-year low. So we're trading at near fiveyear low valuations on the assumption that growth is going to slow because GLP1s have run their course. And I just don't think they have. I think that that pill is going to really extend the market and the sales runway here uh by a lot more than what the street is expecting and pricing in. And the stock again what has been working. Oh, hey, look. This has been working really strong. 1,400 here. Boom. Bursting right through it. Setting new highs. Things look good here. So, I think this is a great stock. It's a great company. I think it's a great stock to hide in or play defense with amidst the recent market turmoil. >> Yeah. Excellent. Um, so with Eli Liy, um, the GLP1 essentially made it a trillion dollar company. Um, do we have a fear of GLP ones running their course? I know you mentioned that just a just a moment ago, but is there a a concern of that in the future once maybe the market is saturated with them? >> Yeah, but I think we're years away from that again. I mean, let just put it here. The the estimates price in saturation happening too soon. So if we push out that saturation point because the pill overperforms, which I think it will, then estimates move higher on a low valuation and the stock works. Like I think it's it's that simple. So this fear of like when it becomes saturated, like yeah, we'll deal with that when we get close to that. I don't think we're close to that. >> Excellent. Okay. Um I guess my question here, we we touched on, you know, two different sectors really. So which which of these stocks do you think offers kind of the best risk adjusted return over the next three to five years? Are we are we looking at the the the AI software layer or the healthcare layer? Uh if you're talking about the next again it depends on on time frame. >> These stocks I'm highlighting as I think great stocks for the next 3 to 6 months. I think there's long-term uh growth potential here too. But I think in the next three to six months, these stocks outperform your AI data center stocks. Then I think in the next three to five years, the AI data center stocks actually kick these stocks ass. Like that's that's what I really believe because I think the trade the AI data center trade is transitioning not ending. The transition is painful and it may not be over. Maybe more shoes to drop if you will, more legs lower, if you will, but eventually we are going to bottom. When we do bottom, I think it's going to be a massive rebound rally. On the other side, as the market adjusts to the new normal of stable but still high capital spending plans from the hyperscalers and stable but still high EPS estimates across the AI supply chain and then boom, we rebound like crazy. So I think in a 3 to 5year window, data center stocks in a 3 to six month window, the application layer starting to look really good. Healthcare looks really good, biotech looks really good. I'm not going to go and chase the consumer staples trading at 30 times earnings for 2% growth. That makes no sense. There are a lot out there right now. Um I wouldn't chase that. I wouldn't play defense there. I would still play offense, but I would play offense away from the the core data center trade until that really starts to stabilize. >> Okay, I think that's a great place to wrap the episode. As always, appreciate the insight, Luke, and we'd like to thank you for tuning in as well. Uh, please make sure to like, comment, and subscribe so we can keep the channel going and flowing. That's being exponential. Signing off. [music]
Comentários 0
Entre para participar da discussão.
EntrarAinda não há comentários. Seja o primeiro a compartilhar sua opinião!